摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-morpholin-4-yl-pyridin-2-ylamine | 1372773-57-3

中文名称
——
中文别名
——
英文名称
5-morpholin-4-yl-pyridin-2-ylamine
英文别名
N-pyridin-2-ylmorpholin-4-amine
5-morpholin-4-yl-pyridin-2-ylamine化学式
CAS
1372773-57-3
化学式
C9H13N3O
mdl
MFCD23713700
分子量
179.222
InChiKey
NUFSJCCFTTVSKK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.444
  • 拓扑面积:
    37.4
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    8-cyclopentyl-2-methanesulfinyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile 、 5-morpholin-4-yl-pyridin-2-ylamine甲苯 为溶剂, 以40%的产率得到8-cyclopentyl-2-(5-morpholin-4-yl-pyridin-2-ylamino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
    参考文献:
    名称:
    Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)
    摘要:
    The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2[-4-(4-methyl-piperazin-l-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARKS kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.
    DOI:
    10.1021/jm401073p
点击查看最新优质反应信息